|Clinical Trial Title||Study of Blood Samples From Newborns With Down Syndrome|
|Trial Status||Closed to Enrollment|
|Trial Type||Pediatric Cancer (Oncology)|
|Specific Condition||Transient Myeloproliferative Disorder (TMD)|
RATIONALE: Studying the genes expressed in samples of blood from patients with Down syndrome may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood samples from newborns with Down syndrome.
|Eligibility Criteria||Age: <90 days of age at diagnosis of Transient Myeloproliferative Disorder (TMD)
Diagnosis of TMD defined as:
Trisomy 21 positive leukemic blasts documented by biopsy of any organ (including >5% non-erythroid/non-lymphoid blasts documented by bone marrow aspirate or biopsy). Infants with isolated trisomy 21 positivity identified only in the leukemic blasts are eligible for study
Enrollment must take place within 21 days following the diagnosis of TMD by a pediatric hematology/oncology specialist
Study status is:
Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.
|Principal Investigator||Janice Olson, MD|
|Contact Name||Children's Cancer and Blood Disorders Program|
|Contact Phone||(503) 276-9300|